Biogen Pharmachem Industries Limited

As of June 30, 2026, Biogen Pharmachem Industries Limited carries a market capitalization of 326.44M, placing it among publicly traded companies globally. Its enterprise value stands at 326.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Biogen Pharmachem Industries Limited has 1.05B shares outstanding.

As of the close on October 22, 2026, Biogen Pharmachem Industries Limited's stock has declined approximately 67.06% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.40.

Over the twelve months ended June 30, 2026, Biogen Pharmachem Industries Limited generated - - in revenue and converted that into -1.67M in net income, yielding earnings per share of 0.00. EBITDA reached -6.04M, while operating income came in at -6.04M.

Biogen Pharmachem Industries Limited's most recent stock split took place on May 15, 2026 with a 6:7 split ratio.